Company intelligence / Profile preview

AprilBio Co., Ltd.

Chuncheon, Gangwon Province, South Koreaaprilbio.com ↗

Ownership: Public · 397030
Development stage: Phase 2

Overview

The company has developed APB-R3 (now EVO301), a long-acting injectable fusion protein designed to neutralize the IL-18 pathway for inflammation regulation. This product has been licensed to Evommune, which plans to initiate Phase 2 clinical trials in early 2025[5].

Therapeutic areas: OncologyRare DiseasesImmunology
Modalities: Antibody fragmentsFusion proteinsLong-acting recombinant protein pharmaceuticals
Industry: Biotech

Drug pipeline

11 assets

APB-R4

Preclinical

10 more assets in the full pipeline.

Request access →

Partnerships

Evommune, Inc. (licensed APB-R3/EVO301)[5]

Beyond the preview

Go deeper on AprilBio Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AprilBio Co., Ltd..

Explore the full profile